Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test | NASDAQ:MYNZ

Proactive InvestorsJul 19 07:20 ET

Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good

This week, Pfizer Inc (NYSE:PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. (NASDAQ:MYNZ) applied for Breakthrough Device Designation to the US Food and Drug Administration (FDA) for its revolutionary colorectal cancer (CRC) screening test, which subject to the review, would significantly accelerate the approval process.

BenzingaJul 10 13:04 ET

Top Premarket Decliners

LegalZoom.com (LZ) shares plunged 28% in recent Wednesday premarket activity after JPMorgan downgraded the company to neutral from overweight and cut its price target to $9 from $14. JMP Securities

MT NewswiresJul 10 07:57 ET

Mainz Biomed Seeks FDA Breakthrough Device Status for Colorectal Cancer Test

Yahoo FinanceJul 10 04:12 ET

Top Premarket Gainers

Pineapple Energy (PEGY) shares climbed more than 67% in recent Tuesday premarket activity, a day after the company said it engaged Conduit Capital for structural internal support, staffing, and

MT NewswiresJul 9 07:57 ET

Express News | Mainz Biomed Shares Are Trading Higher After the Company Announced the Submission for FDA Breakthrough Device Designation for Its CRC Screening Test

BenzingaJul 9 07:57 ET